DKSH aims to improve the lives of patients by providing access to high-quality healthcare throughout the patient journey.

Today, over 6,000 unique rare conditions, from causes, symptoms, treatment to the outcome, have been discovered. Regions around the globe have been conducting research, implementing measures and policies, and formulating treatment programs to provide the best care for the patients having these special conditions.

DKSH brings various stakeholders, including patient associations, pharmaceutical partners, healthcare sectors, and government authorities, to promote understanding, facilitate collaboration, and streamline processes for the benefit of the rare disease patients.

Patient Access

By engaging and connecting pharmaceutical experts, healthcare partners and providers across the globe, DKSH provides high-quality healthcare throughout the entire patient journey.

Affordability

Rare disease treatments involve years of research and development, which explains its substantial financial challenges and subsequently barriers to patient access. DKSH closely works with patient groups and pharmaceutical partners to develop tailored support programs.

Diagnosis

Diagnosis of rare diseases is often rated as one of the greatest challenges, due to their rare, chronic, and complex nature, and insufficient clinical knowledge and the corresponding genetic tests available to all medical professions. DKSH collaborates with various experts and pharmaceuticals to facilitate methods to shortening the journey to diagnosis.

"Healthcare for All" - DKSH promises a better healthcare for all.

With more than 150 years of uninterrupted presence in Asia.

We blend Swiss reliability, professionalism and best practice corporate governance.

Business Unit Healthcare facilitates patient access to quality healthcare products and services in 15 markets across Asia Pacific, including pharmaceutical, over-the-counter (OTC), consumer health and medical device and diagnosis.

We offer a wide range of solutions, from regulatory affairs, patient solution programs, international quality and corporate standards compliance, registration, market entry studies, to marketing and digitalization, logistics and distribution, and after-sales services. Our integrated service offerings are unmatched across the region and have set the benchmark in Asia Pacific.

Our 8,000 healthcare specialists provide deep market knowledge coupled with a breadth of capabilities that enables us to develop truly customized solutions. We support to improve the lives of millions of patients across Asia Pacific.



罕見疾病業務小組

為您的治療旅程 建構優質的醫藥保健

SE DKSH

大昌華嘉以改善病人生活為目標。在整個治療旅程中,為病者提供優質的醫藥保健

時至今天·全球已發現逾6千個罕見的疾病狀況·包括其病因、徵狀、療程至成效結果等。各地持續進行各項相關研究·落實措施及政策·並訂立醫治療程等·為各罕見病患者·提供最適切的關護和治療方案。

大昌華嘉致力凝聚各持分者,包括病人組織、藥業伙伴、醫療業界 及政府機關,以罕見疾病患者的福祉為先,促進互相了解、合作及 改善過程。

獲取治療的機會

透過深化及聯繫對應的全球藥業專研團隊·醫藥保健伙伴及相關的服務提供者·大昌華嘉為病人的治療旅程·提供最優質的醫藥保健。

治療成本負擔

罕見疾病的療程是賴以年計的研究及發展成果·成本相當高昂·形成病人獲取治療的屏障。大昌華嘉與病人組織及藥業伙伴緊密合作·籌劃更適切的治療支援計劃。

縮短診斷時間

罕見疾病的診斷一直是最大的挑戰,除因其罕見、慢性及複雜的病理外,醫學人員亦缺乏所需的臨床知識及對應的基因測試。大昌華嘉與各專業團隊及藥業單位協作,找尋方法,縮短診斷時間。

「Healthcare for All」 - 大昌華嘉承諾為各地提供卓越的醫藥保健

服務亞洲逾150年

集團融匯瑞士業務文化的可靠,專業及最佳的企業管治。

業務單位醫藥保健為遍佈亞太地區的15個市場·助病人獲得優質的 醫藥保健產品及服務·包括藥品·非處方藥品及保健消費品和醫療 器材及診斷儀器。 我們的服務方案廣泛·涵蓋政策事務·病人支援·國際品質及企業合規標準以至註冊·市場拓展研究·推廣及數碼化·物流及分銷和售後服務等。大昌華嘉的整合服務方案於區內無可比擬·亦成為整個亞太地區的行業指標。

超過8千名行業專才透過其深度的市場分析及廣闊的業務能力.助我們發展專項方案。我們為改善亞太地區病人的福祉為業務目標。

